Literature DB >> 1446594

A radioimmunoassay of rat type I iodothyronine 5'-monodeiodinase.

F Santini1, I J Chopra.   

Abstract

A highly sensitive, specific, and reproducible RIA has been developed to measure rat type I iodothyronine 5'-monodeiodinase (5'-MD). A 16-amino acid peptide (LAP-744) corresponding to a portion of the carboxy-terminal region of the rat liver 5'-MD, as predicted from its cDNA, was synthesized, and rabbits were immunized with the peptide-BSA conjugate. In a final dilution of 1:15,000, our anti-5'-MD antibody bound about 30-35% of a tracer amount of [125I]LAP-744. The detection threshold of the RIA approximated 0.08 pmol LAP-744 or an equivalent amount of 0.08 pmol 5'-MD. Rat liver and kidney microsomes produced dose-response curves that were essentially parallel to that of LAP-744. No inhibition of binding of [125I]LAP-744 to antibody was produced by 0.3 mg or less rat microsomal proteins from testes, heart, brain, muscle, spleen, intestine, lung, placenta, or fetal liver. Recovery of nonradioactive LAP-744 added to spleen microsomes averaged 103%. The coefficient of variation averaged 4% within an assay and 11% between assays. In 16 normal rats studied, the mean (+/- SD) 5'-MD content was 2.4 +/- 0.22 pmol/mg protein in liver microsomes and 2.5 +/- 0.27 pmol/mg protein in kidney microsomes. Fasting of the rat for 2-4 days was associated with a significant reduction in both the activity and the content of the 5'-MD in liver and kidney. Hypothyroidism was also associated with a significant decrease in the activity and content of 5'-MD in both tissues. Significant opposite changes were observed in these parameters in hyperthyroidism. Treatment of the rat with sodium ipodate for 3 days was associated with a significant decrease in both the activity and the content of 5'-MD in liver and kidney. A similar treatment of the rat with propylthiouracil induced a clear reduction in the activity of 5'-MD in liver and kidney, but the content of the enzyme was significantly increased in both tissues. Rats treated with aurothioglucose for 3 days exhibited a significant decrease in 5'-MD activity in liver and kidney microsomes, whereas the tissue content of 5'-MD was not affected. A similar treatment of the rat with methimazole had no significant effect on either the activity or the content of 5'-MD.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446594     DOI: 10.1210/endo.131.6.1446594

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome.

Authors:  T Nagaya; M Fujieda; G Otsuka; J P Yang; T Okamoto; H Seo
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  AlphaANP, AVP, and pituitary-thyroid axis in patients with congestive heart failure and acute respiratory failure.

Authors:  S Savastano; V Cannavale; R Valentino; A P Tommaselli; R Rossi; A Luciano; L Tauchmanovà; A Mariano; L Mazzitelli; V Macchia; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

3.  Serum thyroid hormones levels are significantly decreased in septic neonates with poor outcome.

Authors:  A Kurt; A D Aygun; I Sengul; Y Sen; A N Citak Kurt; B Ustundag
Journal:  J Endocrinol Invest       Date:  2010-09-09       Impact factor: 4.256

4.  Clinical investigation: thyroid function test abnormalities in cardiac arrest associated with acute coronary syndrome.

Authors:  Kenan Iltumur; Gonul Olmez; Zuhal Ariturk; Tuncay Taskesen; Nizamettin Toprak
Journal:  Crit Care       Date:  2005-06-09       Impact factor: 9.097

5.  Treatment of Hypothyroid Patients With L-Thyroxine (L-T4) Plus Triiodothyronine Sulfate (T3S). A Phase II, Open-Label, Single Center, Parallel Groups Study on Therapeutic Efficacy and Tolerability.

Authors:  Ferruccio Santini; Giovanni Ceccarini; Caterina Pelosini; Monica Giannetti; Ilaria Ricco; Giorgia Querci; Enzo Grossi; Giorgio Saponati; Paolo Vitti
Journal:  Front Endocrinol (Lausanne)       Date:  2019-11-29       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.